N^1 -Fluoroalkyltryptophan Analogues: Synthesis and *in vitro* Study as Potential Substrates for Indoleamine 2,3-Dioxygenase

Jean Henrottin,^{*,†,‡} Astrid Zervosen,[†] Christian Lemaire,[†] Frédéric Sapunaric,[§] Sophie Laurent,[§] Benoit Van den Eynde,^{||} Serge Goldman,^{⊥,#} Alain Plenevaux,[†] and André Luxen[†]

[†]Cyclotron Research Center, [‡]Department of Chemistry, and [§]Macromolécules Biologiques, Center for Protein Engineering, Université de Liège, Sart-Tilman, B-4000 Liège, Belgium

^{||}Ludwig Institute for Cancer Research, Brussels Branch and de Duve Institute, Université Catholique de Louvain, B-1200 Brussels, Belgium

[⊥]PET/Biomedical Cyclotron Unit and Department of Nuclear Medicine, Erasme Hospital, Université Libre de Bruxelles, B-1070 Brussels, Belgium

[#]Center for Microscopy and Molecular Imaging, Rue Adrienne Bolland 8, B-6041 Gosselies, Belgium

S Supporting Information

ABSTRACT: Indoleamine 2,3-dioxygenase (hIDO) is an enzyme that catalyzes the oxidative cleavage of the indole ring of L-tryptophan through the kynurenine pathway, thereby exerting immunosuppressive properties in inflammatory and tumoral tissues. The syntheses of 1-(2-fluoroethyl)-tryptophan (1-FETrp) and 1-((1-(2-fluoroethyl)-1H-1,2,3-triazol-4-yl)-methyl)-tryptophan, two N^1 -fluoroalkylated tryptophan derivatives, are described here. *In vitro* enzymatic assays with these two new potential substrates of hIDO show that 1-FETrp is a good and specific substrate of hIDO. Therefore, its radioactive isotopomer, 1-[¹⁸F]FETrp, should be a molecule of choice to visualize tumoral and inflammatory tissues and/or to validate new potential inhibitors.

KEYWORDS: Tryptophan, indoleamine 2,3-dioxygenase, kynurenine, 1-(2-fluoroethyl)-tryptophan, tryptophan 2,3-dioxygenase, positron emission tomography

L-Tryptophan (Trp), the least abundant of the essential amino acids, is used in three biological processes: (i) the serotonin pathway, which converts only tiny amounts (about 1%) of dietary Trp into serotonin, (ii) protein synthesis, and (iii) the kynurenine pathway, metabolizing more than 95% of Trp and leading to the biosynthesis of kynurenine (KYN), nicotinamide adenine dinucleotide (NAD⁺), kynurenic acid (KYNA), 3-hydroxyanthranilic acid (3-HAA), etc.^{1–4} The initial and rate-limiting step of the kynurenine pathway requires the involvement of indoleamine 2,3-dioxygenase (hIDO), or tryptophan 2,3-dioxygenase (hTDO; mainly expressed in liver). These structurally different heme-containing enzymes catalyze the C₂–C₃ oxidative cleavage of the pyrrole ring of the indole nucleus of Trp, yielding to the *N*-formyl-L-kynurenine (Scheme 1).^{5–8} hIDO expression is strongly stimulated by interferon- γ (IFN- γ) and also, to some extent, by cytokines such as interleukins (IL-1 β , IL-2) and tumor necrosis factor (TNF- α).^{6,9–15}

hIDO is mainly and highly expressed (i) in placenta, preventing the rejection of allogeneic fetuses,⁵ (ii) in inflammatory tissues,^{11,12} and (iii) in human tumors such as mammary, prostatic, colorectal, pancreatic, cervical, and endometrial carcinomas.^{4,5,11–15} In these various tissues, this high expression of hIDO creates a depletion of tryptophan and an

Scheme 1. The Two First Steps of the Kynurenine Pathway^a

^aL-Kynurenine, the key intermediate of the kynurenine pathway, is formed from L-tryptophan in two steps catalyzed by indoleamine 2,3-dioxygenase (or tryptophan 2,3-dioxygenase) and formamidase, respectively.

accumulation of immunosuppressive tryptophan catabolites, both of which result in a local suppression of the immune response by blocking T-lymphocyte proliferation in the G1 phase of the cell cycle.^{1,5,7,16,17}

Recently, in order to improve cancer immunotherapy and to counteract the local immunosuppression that protects malignancies from endogenous and drug-induced destruction, a number of hIDO inhibitors have been developed.¹⁸ To facilitate

Received: September 22, 2014

Accepted: January 25, 2015

Published: January 25, 2015

Scheme 2. General Scheme for the Syntheses of 1-(2-Fluoroethyl)-tryptophan (**5**) and 1-((1-(2-Fluoroethyl)-1*H*-1,2,3-triazol-4-yl)methyl)-tryptophan (**10**)

(i) the preclinical and clinical development and validation of such compounds and (ii) the clinical detection of hIDO expressing cells in cancer imaging, the synthesis (and the radiosynthesis) of a PET imaging tracer could prove to be a highly desirable and valuable tool.

$[\alpha/\beta\text{-}^{11}\text{C}]$ -L-Tryptophan,^{19,20} 5-hydroxy- $[\alpha/\beta\text{-}^{11}\text{C}]$ -L-tryptophan,^{20,21} and $\alpha\text{-}[^{11}\text{C}]$ methyl-L-tryptophan ($[^{11}\text{C}]$ AMT)^{15,21–23} are radiotracers used essentially in positron emission tomography (PET) studies of the *in vivo* transport and brain serotonin metabolism of L-tryptophan in health and disease.

Inasmuch as following the metabolization of a radioactive substrate of hIDO through the kynurenine pathway could highlight the presence of this enzyme, the introduction into tryptophan of a radionuclide with a longer half-life time, such as $[^{18}\text{F}]$ fluorine ($t_{1/2} = 109.7$ min), seems to be better adapted than $[^{11}\text{C}]$ carbon ($t_{1/2} = 20.3$ min) (in terms of $[^{18}\text{F}]$ fluorine production, radiotracer synthesis, biological studies over longer periods, etc.).

In order to achieve these objectives, two molecules alkylated on the nitrogen atom of the indole ring, 1-(2-fluoroethyl)-tryptophan (**5**) and 1-((1-(2-fluoroethyl)-1*H*-1,2,3-triazol-4-yl)methyl)-tryptophan (**10**) (Scheme 2), were synthesized using two different approaches (including a “Click” reaction), both easily transposable for the radiosynthesis.

The synthesis of the key intermediate **2**, used for those of **5** and **10** (Scheme 2), involved the protection of the carboxylic acid function of the commercially available Boc-L-tryptophan **1** with *tert*-butyl ester (27%). The synthesis of **5**, allowing the introduction in two steps of a fluoroethyl group, one of the smallest monofluoroalkyl chains, required the N^1 -alkylation of **2** with 1-fluoro-2-tosyloxyethane (**3**) (1.1 equiv; synthesized beforehand from 2-fluoroethanol **6** (95%)) with sodium hydride (2.5 equiv) at 0°C in DMF. These conditions were crucial to minimize side reactions while maximizing the yield of the N^1 -alkylation (52%). Hydrolysis of the intermediate **4** in hydrochloric acid (6 N) and 1,4-dioxane (1/1 (v/v)) then gave 1-(2-fluoroethyl)-tryptophan as its hydrochloride salt (**5**·HCl; 93%). The enantiomeric excess was determined for **5** by a chiral HPLC analysis. A racemization of the α -amino acid product was observed. However, our method using sodium hydride offered a better yield (52%) compared with that recently obtained by Sun et al. (NaOH, 30%). Moreover, epimerization was not evaluated in this paper.²⁴

The synthesis of **10** began with the N^1 -alkylation of **2** with propargyl bromide (5 equiv) and sodium hydride (5 equiv) at 0°C

for 5 h in DMF (93%). This result was in good accordance with that obtained by Schultz et al.²⁵ The 1,2,3-triazole ring was formed by a Huisgen 1,3-dipolar cycloaddition (also known as a Click reaction), usually catalyzed by copper(I) salt (directly introduced or generated *in situ*) in conjunction with an added organic or inorganic base.^{26–28} This synthesis allowed an easy introduction of the fluorine, leading to a longer and more rigid monofluorinated chain, due to a triazole ring formation between **7** and the fluorinated prosthetic group **8** (synthesized beforehand in one step from **3** and sodium azide), at room temperature for 7 h. The reusable polymer-supported Amberlyst A-21-CuI, which associates an organic base and Cu(I) salt, should facilitate Cu(I) elimination.²⁸ However, even though the yields obtained were good (73%), after an extended stirring, copper was partially released into the solution. Copper(I) iodide offered the desired product but with a small amount of 5-iodo-1,2,3-triazole derivative as an unwanted side-product. The Hünig’s base and tetrakis(acetonitrile)copper(I) hexafluorophosphate ($\text{Cu}(\text{CH}_3\text{CN})_4\text{PF}_6$), which is much more soluble than CuI,²⁸ gave higher yields (81%) while limiting the number of side-products. Nevertheless, an inert atmosphere is essential to limit the formation of the 5-hydroxy-1,2,3-triazole analogue. Finally, hydrolysis of **9** in hydrochloric acid (6 N) and 1,4-dioxane (1/1 (v/v)) offered 1-((1-(2-fluoroethyl)-1*H*-1,2,3-triazol-4-yl)methyl)-tryptophan as its hydrochloride salt (**10**·HCl) (83%). A complete racemization of the α -amino acid product was also observed.

In vitro enzymatic assays with **5** and **10** were performed in order to characterize the affinity and the specificity of these new potential substrates for recombinant human indoleamine 2,3-dioxygenase (rhIDO) (Scheme 1; see Supporting Information for experimental details). This reaction has been widely studied, and substrates have been characterized by kinetic constants determined through the use of a range of analytical methods, observing either the formation of *N*-formyl-L-kynurenine derivatives (direct method)^{29,30} or an increase in the concentration of L-kynurenine analogues after incubation with perchloric acid (indirect method).^{31–33}

The formation of the product, *N*-formyl-L-kynurenine, was followed by measuring its absorbance at 321 nm.^{30–32} Nevertheless, as mentioned briefly by Chauhan et al.,³¹ the UV-absorbance of the *N*-formyl-L-kynurenine derivative decreased significantly when the nitrogen in the substrate was alkylated, as for 1-Me-L-Trp (**12**). This decrease was also observed here for 1-FETrp (**5**), where the low UV-absorption

Table 1. Enzymatic Assays Carried out under Different Conditions with Some Substrates and NON Substrates of rhIDO

substrates or NON substrates tested		percentage of substrate consumed after incubation			
		[rhIDO] Time	5 μ M 4 h	0.5 μ M 1 h	0.1 μ M 1 h
		[Substrate]	1000 μ M	100 μ M	100 μ M
	L-Trp 11		100% ^e	100% ^f	94% ^f
	1-Me-L-Trp ^a 12		100% ^e	>99% ^f	34% ^f
	5-HO-L-Trp ^a 13		100% ^e	67% ^f	13% ^f
	1-FETrp ^b 5		100% ^e	27% ^f	7% ^f
	α -Me-DL-Trp ^a 14		0% ^e	nd	nd
	Tryptamine ^c 15		0% ^e	nd	nd
	α -Me-DL-Tryptamine ^c 16		0% ^e	nd	nd
	Boc-L-Trp ^d 17		0% ^e	nd	nd
	Ac-L-Trp ^a 18		0% ^e	nd	nd
	1-((1-(2-fluoroethyl)- <i>1H</i> -1,2,3-triazol-4- yl)methyl)-tryptophan ^b 10		0% ^e	nd	nd

^aFrom Aldrich. ^bRacemate. ^cAcros Organics. ^dIris Biotech GmbH. ^ePercentage determined by UV detection method. ^fPercentage obtained by fluorescence detection method. All assays were repeated two to three times. nd: not determined.

of the product did not allow the study of the reaction by this method. An indirect method was therefore investigated. Moreover, it was observed that *N*-alkylated-*N*-formyl-kynurenine derivatives were hydrolyzed into *N*-alkylated-kynurenine analogues much more slowly (for at least 30 min in HClO₄). The substrates and their products were separated by HPLC or UPLC and

detected by UV (method A, less sensitive; [S] $\geq$ 200 μ M) or by fluorescence detection (method B; used to detect only the substrates; [S] $\geq$ 2 μ M).³⁴

The oxidative conditions of the enzymatic reaction were first improved to allow a complete oxidation of the natural substrate: L-tryptophan (**11**) (Table 1). Under these optimal conditions,

Table 2. *In vitro* Enzymatic Assays Performed with rhIDO (37 °C, pH 6.5)

substrate	K_m	k_{cat}/K_m^a
L-Trp (11)	$15 \pm 2 \mu M^b$	$2100.10^2 M^{-1} s^{-1b}$
1-Me-L-Trp (12)	$62 \pm 9 \mu M^b$	$(38 \pm 17).10^2 M^{-1} s^{-1}$
5-HO-L-Trp (13)	$17 \pm 1.1 \mu M^c$	$(21 \pm 4).10^2 M^{-1} s^{-1}$
1-FETrp (5) ^d	$70 \pm 30 \mu M^e$	$(5.8 \pm 0.7).10^2 M^{-1} s^{-1}$

^aRatios determined by measurement of the substrate concentration in relation to the incubation time (method B). ^bValues determined by Lu et al.³⁰ ^cValues determined by Basran et al.²⁹ ^dRacemate. ^eConstant obtained by initial-rate determination (method B).

12, 13, and 5 were also completely oxidized. These results were in contrast to those found with the following six compounds: 10 (which probably had a too long and rigid substituent to fit adequately into the catalytic cavity of the enzyme); α -Me-DL-Trp (14); tryptamine (15); α -Me-DL-tryptamine (16); Boc-L-Trp (17); and Ac-L-Trp (18) (whose NH_3^+ group is protected and no longer available for H-bonding interaction with the catalytic center facilitating the ring-opening reaction⁷). These six

compounds were therefore found not to be substrates of this enzyme. In our experimental conditions, the opening of the indole ring was also not observed for α -Me-DL-Trp (AMT, 14). Thus, our results showed that AMT was not metabolized by rhIDO through the kynurenine pathway, contrary to the findings reported in the literature.³⁵

The incubation conditions (substrate concentration, enzyme concentration, and time) were then changed in order to compare the substrates. Compound 5 was identified as a good substrate of this enzyme, but it was found to be oxidized more slowly than 5-HO-L-Trp (around 2 times), 1-Me-L-Trp (around 4 times), and L-Trp, which is known as the best substrate for rhIDO (Table 1).

The fluorescence method was used to determine the initial rates, allowing the determination of the K_m and k_{cat} values. An inhibition by the substrate was observed for L-Trp and 1-Me-L-Trp, as described in the literature,³⁰ but not for 5-HO-L-Trp and 1-FETrp under the conditions studied. However, even though the concentration of rhIDO was reduced as much as possible, the reaction was still too fast to allow an accurate determination

Scheme 3. General Enzymatic Oxidative Indole Ring Opening of rhIDO Substrates and Hydrolysis in Perchloric Acid **Table 3.** HPLC Analyses of the Enzymatic Assays of L-Tryptophan and Derivatives with rhIDO (Retention Times and MS)

Molecules tested	Retention times of tryptophan analogues ^{a,b}	Structure, retention times ^{a,c} and principal mass peak ^d observed for <i>N</i> -formyl-kynurenine analogues	Structure, retention times ^{a,c} and principal mass peak ^d observed for kynurenine analogues
L-Trp (11)	5.4 min	4.3 min $m/z = 237$ [$M_{for-kyn} + H$]	4.5 min $m/z = 209$ [$M_{kyn} + H$]
1-Me-L-Trp (12)	9.4 min	4.5 min $m/z = 251$ [$M_{for-kyn} + H$]	7.4 min $m/z = 223$ [$M_{kyn} + H$]
5-HO-L-Trp (13)	5.1 min ^e	n.o.	3.9 min ^e $m/z = 225$ [$M_{kyn} + H$]
1-FETrp (5) ^f	9.2 min	5.0 min $m/z = 283$ [$M_{for-kyn} + H$]	7.9 min $m/z = 255$ [$M_{kyn} + H$]

Molecules tested that were found not to be substrates: 10^f (rt: 16.4 min), α -Me-DL-Trp (14) (rt: 7.0 min), tryptamine (15) (rt: 9.0 min), α -Me-DL-tryptamine (16) (rt: 11.1 min), Boc-L-Trp (17) (rt: 5.9 min) and Ac-L-Trp (18) (rt: 7.0 min)

^aRetention times determined by HPLC analyses (or UPLC analyses; see Supporting Information). Elution conditions: CH_3CN /ammonium acetate (10 mM), 10/90 (v/v), flow 0.7 mL/min. ^bUV detection (method A) at 221 and 284 nm. ^cUV detection (method A) at 321 or 360 nm. ^dMass spectra (see Supporting Information). ^eRetention times determined by HPLC analyses (or UPLC analyses; see Supporting Information). Elution conditions: CH_3CN /ammonium acetate (10 mM), 5/95 (v/v), flow 0.7 mL/min. ^fRacemate. n.o.: not observed because hydrolysis of the formyl substituent was too fast in these conditions.

of the initial rates. Nonetheless, these results still allowed an estimation of the K_m value ($70 \pm 30 \mu\text{M}$ for 1-FETrp).

Because of the difficulties involved in determining accurately these kinetic constants, the k_{cat}/K_m ratio, a second order constant, characterizing the reaction rate for substrate concentrations smaller than K_m (values summarized in Table 2), was determined via method B.^{29,30} The oxidation rate of **5** was smaller than for **13** (around 3 times), **12** (6 times), and **11** (360 times) (Table 2; Supporting Information), suggesting that, having a more sterically hindered structure than L-Trp, **5** has lesser conformational freedom in the catalytic cavity, reducing the flexibility of its complex with rhIDO and undoubtedly conducting to a slower enzymatic reaction.

HPLC and UPLC analyses were performed, and the two product peaks appearing on the chromatograms for **11**, **12**, **13** (only one peak), and **5** (see Supporting Information) were collected and analyzed in mass spectrometry (Table 3). These analyses confirmed that the products formed were kynurenine and *N*-formyl-kynurenine derivatives (Scheme 3). Accurate mass determination was performed on *N*-fluoroethyl-*N*-formyl-kynurenine (**19**) (FT-MS (positive): $m/z = 283.108862$ (calculated), 283.108707 (measured) $[M + H]^+$) and *N*-fluoroethyl-kynurenine (**20**) (FT-MS (positive): $m/z = 255.113947$ (calculated), 255.113825 (measured) $[M + H]^+$) confirming the nature of these compounds.

Similar *in vitro* enzymatic assays with recombinant human tryptophan 2,3-dioxygenase (rhTDO; Scheme 1) were performed to determine the specificity of the substrates (**11**, **12**, **13**, and **5**) for rhIDO.^{36,37} The solutions obtained after incubation and the addition of perchloric acid were analyzed by HPLC with fluorescence detection. As expected, L-tryptophan was found to be an excellent substrate of rhTDO, while 5-HO-L-Trp was a poor substrate. 1-FETrp and 1-Me-L-Trp, however, were found not to be substrates (Table 4). For the highest

Table 4. *In vitro* Enzymatic Assays Performed with rhTDO (37 °C, pH 7.5)

substrates tested	percentage of substrate consumed after 1 h of incubation	
	rhTDO 1 μM	rhTDO 10 μM
L-Trp (11)	67% ^a	100% ^a
1-Me-L-Trp (12)	0% ^a	3% ^a
5-HO-L-Trp (13)	0% ^a	14% ^a
1-FETrp (5) ^b	0% ^a	2% ^a

^aSubstrate concentration: 100 μM . ^bRacemate.

enzyme concentration tested, consumption of only 2 or 3% of 1-FETrp and 1-Me-L-Trp was observed, but these uptakes were too low to consider these molecules as substrates of rhTDO. This specificity of **5** (and *a fortiori* for **12**) could be explained by a broader substrate-selectivity of rhIDO due to a higher flexibility of its heme as compared to that of rhTDO.⁸

In summary, this letter describes the synthesis of two tryptophan derivatives, **5** and **10**, both modified on the nitrogen of the indole ring. These compounds were tested as potential substrates of rhIDO. *In vitro* enzymatic assays with 1-FETrp show that this molecule is a good and specific substrate of rhIDO but that it is not a substrate of rhTDO. Unfortunately, **10** is found not to be a substrate of rhIDO.

As **5** shows encouraging results in the *in vitro* enzymatic assays, a simplified n.c.a. radiosynthesis of 1-(2-[¹⁸F]-fluoroethyl)-tryptophan (1-[¹⁸F]FETrp) could be designed. This radioactive

isotopomer, currently being developed in our laboratory, could be a valuable tool for the preclinical and the clinical validation of new potential inhibitors. Furthermore, 1-[¹⁸F]FETrp could also facilitate a more specific detection of hIDO expressing cells in cancer imaging.

■ ASSOCIATED CONTENT

Supporting Information

Experimental sections, enzymatic equations, enzymatic curves obtained with **5**, NMR analyses of some compounds (**4**, **5**, **9**, and **10**), UPLC chromatograms, and mass spectra of the rhIDO substrates. This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: jean.henrotin@ulg.ac.be. Phone: (+32)43663383. Fax: (+32)43662946.

Funding

The authors gratefully acknowledge the Region Wallonne (Keymarker Project and Cantol Project (BioWin)) for their financial support. Alain Plenevaux is a senior research associate from FRS-FNRS Belgium.

Notes

The authors declare no competing financial interest.

■ ABBREVIATIONS

AMT, α -methyl-L-tryptophan; 1-FETrp, 1-(2-fluoroethyl)-tryptophan; 3-HAA, 3-hydroxyanthranilic acid; hIDO, human indoleamine 2,3-dioxygenase; IFN- γ , interferon- γ ; KYN, kynurenine; KYNA, kynurenic acid; NAD⁺, nicotinamide adenine dinucleotide; hTDO, human tryptophan 2,3-dioxygenase; Trp, L-tryptophan

■ REFERENCES

- (1) Vecsei, L.; Szalardy, L.; Fulop, F.; Toldi, J. Kynurenes in the CNS: recent advances and new questions. *Nat. Rev. Drug Discovery* **2013**, *12*, 64–82.
- (2) Platten, M.; Wick, W.; Van den Eynde, B. J. Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. *Cancer Res.* **2012**, *72*, 5435–5440.
- (3) Takikawa, O. Biochemical and medical aspects of the indoleamine 2,3-dioxygenase-initiated L-tryptophan metabolism. *Biochem. Biophys. Res. Commun.* **2005**, *338*, 12–19.
- (4) Adams, S.; Braid, N.; Bessesde, A.; Brew, B. J.; Grant, R.; Teo, C.; Guillemin, G. J. The kynurenine pathway in brain tumor pathogenesis. *Cancer Res.* **2012**, *72*, 5649–5657.
- (5) Uyttenhove, C.; Pilotte, L.; Theate, I.; Stroobant, V.; Colau, D.; Parmentier, N.; Boon, T.; Van den Eynde, B. J. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. *Nat. Med.* **2003**, *9*, 1269–1274.
- (6) Macchiarulo, A.; Camaioni, E.; Nuti, R.; Pellicciari, R. Highlights at the gate of tryptophan catabolism: a review on the mechanisms of activation and regulation of indoleamine 2,3-dioxygenase (IDO), a novel target in cancer disease. *Amino Acids* **2009**, *37*, 219–229.
- (7) Capece, L.; Lewis-Ballester, A.; Yeh, S.-R.; Estrin, D. A.; Marti, M. A. The complete reaction mechanism of indoleamine 2,3-dioxygenase as revealed by QM/MM simulations. *J. Phys. Chem. B* **2012**, *116*, 1401–1413.
- (8) Lewis-Ballester, A.; Batabyal, D.; Egawa, T.; Lu, C.; Lin, Y.; Marti, M. A.; Capece, L.; Estrin, D. A.; Yeh, S.-R. Evidence for a ferryl intermediate in a heme-based dioxygenase. *Proc. Natl. Acad. Sci. U.S.A.* **2009**, *106*, 17371–17376.

- (9) Myint, A. M.; Kim, Y. K. Cytokine–serotonin interaction through IDO: a neurodegeneration hypothesis of depression. *Med. Hypotheses* **2003**, *61*, 519–525.
- (10) Maes, M.; Leonard, B. E.; Myint, A. M.; Kubera, M.; Verkerk, R. The new ‘S-HT’ hypothesis of depression: Cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **2011**, *35*, 702–721.
- (11) Wainwright, D. A.; Balyasnikova, I. V.; Chang, A. L.; Ahmed, A. U.; Moon, K.-S.; Auffinger, B.; Tobias, A. L.; Han, Y.; Lesniak, M. S. IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. *Clin. Cancer Res.* **2012**, *18*, 6110–6121.
- (12) Munn, D. H.; Mellor, A. L. Indoleamine 2,3-dioxygenase and metabolic control of immune responses. *Trends Immunol.* **2013**, *34*, 137–143.
- (13) Kwidzinski, E.; Bechmann, I. IDO expression in the brain: a double-edged sword. *J. Mol. Med.* **2007**, *85*, 1351–1359.
- (14) Muller, A. J.; Prendergast, G. C. Indoleamine 2,3-dioxygenase in immune suppression and cancer. *Curr. Cancer Drug Targets* **2007**, *7*, 31–40.
- (15) Juhász, C.; Nahleh, Z.; Zitron, I.; Chugani, D. C.; Janabi, M. Z.; Bandyopadhyay, S.; Ali-Fehmi, R.; Mangner, T. J.; Chakraborty, P. K.; Mittal, S.; Muzik, O. Tryptophan metabolism in breast cancers: molecular imaging and immunohistochemistry studies. *Nucl. Med. Biol.* **2012**, *39*, 926–932.
- (16) Mellor, A. L.; Munn, D. H. Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? *Immunol. Today* **1999**, *20*, 469–473.
- (17) Munn, D. H.; Mellor, A. L. IDO and tolerance to tumors. *Trends Mol. Med.* **2004**, *10*, 15–18.
- (18) Dolušić, E.; Frédérick, R. Indoleamine 2,3-dioxygenase inhibitors: a patent review (2008 – 2012). *Expert Opin. Ther. Pat.* **2013**, *23*, 1367–1381.
- (19) Washburn, L. C.; Sun, T. T.; Byrd, B. L.; Hayes, R. L.; Butler, T. A. DL-[Carboxyl-¹¹C]tryptophan, a potential agent for pancreatic imaging: production and preclinical investigations. *J. Nucl. Med.* **1979**, *20* (8), 857–864.
- (20) Hartvig, P.; Lindner, K. J.; Tedroff, J.; Andersson, Y.; Bjurling, P.; Långström, B. Brain kinetics of ¹¹C-labelled L-tryptophan and 5-hydroxy-L-tryptophan in the Rhesus monkey. A study using positron emission tomography. *J. Neural Transm.* **1992**, *88* (1), 1–10.
- (21) Lundquist, P.; Hartvig, P.; Blomquist, G.; Hammarlund-Udenaes, M.; Långström, B. 5-Hydroxy-L-[¹¹C]tryptophan versus α -[¹¹C]methyl-L-tryptophan for positron emission tomography imaging of serotonin synthesis capacity in the rhesus monkey brain. *J. Cereb. Blood Flow Metab.* **2006**, *27* (4), 821–830.
- (22) Juhász, C.; Muzik, O.; Chugani, D. C.; Chugani, H. T.; Sood, S.; Chakraborty, P. K.; Barger, G. R.; Mittal, S. Differential kinetics of α -[¹¹C]methyl-L-tryptophan on PET in low-grade brain tumors. *J. Neuro-Oncol.* **2011**, *102*, 409–415.
- (23) Gharib, A.; Balende, C.; Sarda, N.; Weissmann, D.; Plenevaux, A.; Luxen, A.; Bobillier, P.; Pujol, J.-F. Biochemical and autoradiographic measurements of brain serotonin synthesis rate in the freely moving rat: a reexamination of the α -methyl-L-tryptophan method. *J. Neurochem.* **1999**, *72*, 2593–2600.
- (24) Sun, T.; Tang, G.; Tian, H.; Wang, X.; Chen, X.; Chen, Z.; Wang, S. Radiosynthesis of 1-[¹⁸F]fluoroethyl-L-tryptophan as a novel potential amino acid PET tracer. *Appl. Radiat. Isot.* **2012**, *70*, 676–680.
- (25) Schultz, A. W.; Lewis, C. A.; Luzung, M. R.; Baran, P. S.; Moore, B. S. Functional characterization of the cyclomarin/cyclomarine prenyltransferase CymD directs the biosynthesis of unnatural cyclic peptides. *J. Nat. Prod.* **2010**, *73*, 373–377.
- (26) Girard, C.; Önen, E.; Aufort, M.; Beauvière, S.; Samson, E.; Herscovici, J. Reusable polymer-supported catalyst for the [3 + 2] Huisgen cycloaddition in automation protocols. *Org. Lett.* **2006**, *8*, 1689–1692.
- (27) Bock, V. D.; Hiemstra, H.; van Maarseveen, J. H. Cu^I-catalyzed alkyne-azide “click” cycloadditions from a mechanistic and synthetic perspective. *Eur. J. Org. Chem.* **2006**, *2006*, 51–68.
- (28) Crumpton, J. B.; Santos, W. L. Site-specific incorporation of diamondoids on DNA using click chemistry. *Chem. Commun.* **2012**, *48*, 2018–2020.
- (29) Basran, J.; Rafice, S. A.; Chauhan, N.; Efimov, I.; Cheesman, M. R.; Ghamsari, L.; Raven, E. L. A kinetic, spectroscopic, and redox study of human tryptophan 2,3-dioxygenase. *Biochemistry* **2008**, *47*, 4752–4760.
- (30) Lu, C.; Lin, Y.; Yeh, S.-R. Inhibitory substrate binding site of human indoleamine 2,3-dioxygenase. *J. Am. Chem. Soc.* **2009**, *131*, 12866–12867.
- (31) Chauhan, N.; Thackray, S. J.; Rafice, S. A.; Eaton, G.; Lee, M.; Efimov, I.; Basran, J.; Jenkins, P. R.; Mowat, C. G.; Chapman, S. K.; Raven, E. L. Reassessment of the reaction mechanism in the heme dioxygenases. *J. Am. Chem. Soc.* **2009**, *131*, 4186–4187.
- (32) Basran, J.; Efimov, I.; Chauhan, N.; Thackray, S. J.; Krupa, J. L.; Eaton, G.; Griffith, G. A.; Mowat, C. G.; Handa, S.; Raven, E. L. The mechanism of formation of N-formylkynurenine by heme dioxygenases. *J. Am. Chem. Soc.* **2011**, *133*, 16251–16257.
- (33) Fujigaki, H.; Saito, K.; Lin, F.; Fujigaki, S.; Takahashi, K.; Martin, B. M.; Chen, C. Y.; Masuda, J.; Kowalak, J.; Takikawa, O.; Seishima, M.; Markey, S. P. Nitration and inactivation of IDO by peroxynitrite. *J. Immunol.* **2006**, *176*, 372–379.
- (34) Meisel, R.; Zibert, A.; Laryea, M.; Göbel, U.; Däubener, W.; Dilloo, D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. *Blood* **2004**, *103*, 4619–4621.
- (35) Zitron, I. M.; Kamson, D. O.; Kiouisis, S.; Juhász, C.; Mittal, S. In vivo metabolism of tryptophan in meningiomas is mediated by indoleamine 2,3-dioxygenase 1. *Cancer Biol. Ther.* **2013**, *14*, 333–339.
- (36) Dolušić, E.; Larrieu, P.; Moineaux, L.; Stroobant, V.; Pilotte, L.; Colau, D.; Pochet, L.; Van den Eynde, B. t.; Masereel, B.; Wouters, J.; Frédérick, R. Tryptophan 2,3-Dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators. *J. Med. Chem.* **2011**, *54*, 5320–5334.
- (37) Dolušić, E.; Larrieu, P.; Blanc, S.; Sapunaric, F.; Pouyez, J.; Moineaux, L.; Colette, D.; Stroobant, V.; Pilotte, L.; Colau, D.; Ferain, T.; Fraser, G.; Galleni, M.; Frère, J.-M.; Masereel, B.; Van den Eynde, B.; Wouters, J.; Frédérick, R. Discovery and preliminary SARs of keto-indoles as novel indoleamine 2,3-dioxygenase (IDO) inhibitors. *Eur. J. Med. Chem.* **2011**, *46*, 3058–3065.